摘要:
The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.
摘要:
A delivery device (100,200) is disclosed, which comprises a container (80) containing a dose of greater than 40mg of a powder and having at least one exit orifice (92) for dispensing the dose from the container (80), and a chamber (110) adapted to receive the container (80) in an operative configuration, the delivery device (100,200) further comprising at least one gas inlet (26) by which gas may enter the chamber (110) and at least one gas outlet (72) by which gas and entrained powder may exit the chamber (110), wherein the delivery device (100,200) is operable to generate a gas flow through the chamber (110) between the at least one gas inlet (26) and the at least one gas outlet (72), which brings about orbital motion of the container (80) within the chamber (110) in that at least a central region of the container (80) orbits a central axis of the chamber (110).
摘要:
The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.